AHNAK2 and neoplasm: Patients with NSCLC harboring AHNAK2 mutations exhibit higher tumor mutation burden (TMB), indicating enhanced tumor immunogenicity, and these mutations are associated with an activated immune microenvironment, marked by increased immune cell infiltration and activation (55).